Adenoviral Vectors: Potential as Anti-HBV Vaccines and Therapeutics.
Genes (Basel)
; 13(11)2022 10 25.
Article
in English
| MEDLINE | ID: covidwho-2090054
ABSTRACT
Adenoviral vaccines have been at the front line in the fight against pandemics caused by viral infections such as Ebola and the coronavirus disease 2019. This has revived an interest in developing these vectors as vaccines and therapies against other viruses of health importance such as hepatitis B virus (HBV). Current hepatitis B therapies are not curative; hence, chronic hepatitis B remains the major risk factor for development of liver disease and death in HBV-infected individuals. The ability to induce a robust immune response and high liver transduction efficiency makes adenoviral vectors attractive tools for anti-HBV vaccine and therapy development, respectively. This review describes recent developments in designing adenoviral-vector-based therapeutics and vaccines against HBV infection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Viral Vaccines
/
Hepatitis B, Chronic
/
COVID-19
/
Hepatitis B
Type of study:
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Year:
2022
Document Type:
Article
Affiliation country:
Genes13111941
Similar
MEDLINE
...
LILACS
LIS